Oral Cancer News | Tag Archive

Combo HPV Diagnostic Test for Head and Neck Cancer Outperforms Other Tests

Thursday, October 6, 2011

SOURCE: American Association for Cancer Research PHILADELPHIA — October 3, 2011 — Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinomas which derive from human papillomavirus (HPV) type 16, according to a study published in Clinical Cancer Research. “This [...]

Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination

Tuesday, October 4, 2011

0 Comments

Source: Clinical Cancer Research Abstract Purpose: Human papillomavirus-16 (HPV16) is the causative agent in a biologically distinct subset of oropharyngeal squamous cell carcinoma (OPSCC) with highly favorable prognosis. In clinical trials, HPV16 status is an essential inclusion or stratification parameter, highlighting the importance of accurate testing. Experimental Design: Fixed and fresh-frozen tissue from 108 OPSCC [...]

New Improved HPV Diagnostic Test for Head and Neck Cancer

Tuesday, October 4, 2011

0 Comments

Source: EurekAlert! Philadelphia — Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association [...]

Increase in oral cancers linked to HPV

Monday, October 3, 2011

1 Comment

Source: thechart.blogs.cnn.com Author: Saundra Young – CNN Medical Senior Producer The human papillomavirus is contributing to the growing number of head and neck cancers in the United States, according to a new study Monday in the Journal of Clinical Oncology. The study found that the number of cases of oropharyngeal cancer – cancers of the [...]

HIM study looks at HPV infection and clearance in men

Friday, March 4, 2011

0 Comments

Medscape Oncology News By Nick Mulcahy March 1, 2011 — Half of all the men participating in a natural history study of human papillomavirus (HPV) were infected with some strain of HPV at some point during study period, according to the results of a new study published online March 1 in the Lancet. The HPV in [...]

Oropharyngeal cancer epidemic and human papillomavirus

Sunday, November 7, 2010

0 Comments

Source: www.foodconsumer.org Authors: Torbjörn Ramqvist and Tina Dalianis Abstract A growing body of research shows that human papillomavirus (HPV) is a common and increasing cause of oropharyngeal squamous cell carcinoma (OSCC). Thus, the International Agency for Research against Cancer has acknowledged HPV as a risk factor for OSCC, in addition to smoking and alcohol consumption. [...]

European Commission amends licence for Cervarix

Wednesday, August 25, 2010

0 Comments

Source: www.pharmpro.com Author: press release GlaxoSmithKline (GSK) confirmed today that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication. [...]

HPV is changing the face of head and neck cancers

Sunday, June 27, 2010

0 Comments

Source: www.hemonctoday.com Author: Christen Cona In February, at the Multidisciplinary Head and Neck Cancer Symposium in Chandler, Ariz., Maura Gillison, MD, PhD, professor and Jeg Coughlin Chair of Cancer Research at The Ohio State University in Columbus, presented data that showed that the proportion of all head and neck squamous cell cancers that were of [...]

BT Pharma secures EUR 13.1million (USD 17.7 million) in capital funding and changes its name to Genticel

Tuesday, March 9, 2010

0 Comments

Source: pharmalive.com/News Author: press release BT Pharma, a biopharmaceutical company developing innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today that it has raised EUR 13.1 million in additional funding and changed its name to Genticel. AGF Private Equity led the round, which brought in three new investors, IRDI (Institut Régional [...]

Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma

Saturday, December 19, 2009

0 Comments

Source: Journal of Clinical Oncology, Vol 27, No 36 (December 20), 2009: pp. 6213-6221 Authors: Wei Shi et al. Purpose: A significant proportion of oropharyngeal squamous cell carcinomas (OSCC) are associated with the human papilloma virus (HPV), particularly HPV16. The optimal method for HPV determination on archival materials however, remains unclear. We compared a quantitative [...]

Tag Archive | "HPV16"